Inclusion Body Myositis Clinical Trial
Official title:
Evaluation of Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Comparison of a group of 20 IBM patients with 20 controls matched on age, gender and weight.
n/a
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00769860 -
Arimoclomol in Sporadic Inclusion Body Myositis
|
Phase 2/Phase 3 | |
| Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
| Active, not recruiting |
NCT05046821 -
Sporadic Inclusion Body Myositis Natural History Study
|
||
| Recruiting |
NCT06153108 -
Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
|
||
| Active, not recruiting |
NCT04659031 -
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
|
Phase 1 | |
| Completed |
NCT03440034 -
Study of Pioglitazone in Sporadic Inclusion Body Myositis
|
Phase 1 | |
| Terminated |
NCT04049097 -
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
|
Phase 3 | |
| Completed |
NCT00001261 -
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
|
Phase 2 | |
| Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
| Completed |
NCT01734369 -
Environmental Risk Factors for Myositis in Military Personnel
|
||
| Active, not recruiting |
NCT04975841 -
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
|
N/A | |
| Recruiting |
NCT00017914 -
Adult and Juvenile Myositis
|
||
| Completed |
NCT00917956 -
Lithium in Inclusion Body Myositis (IBM)
|
N/A | |
| Completed |
NCT03633318 -
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
|
||
| Recruiting |
NCT04789070 -
Phase III Trial of Sirolimus in IBM
|
Phase 3 | |
| Active, not recruiting |
NCT05721573 -
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05032131 -
Cell Therapy for IBM by Muscle Injection of ADSVF
|
Phase 1 | |
| Completed |
NCT03299335 -
Molecular Profile of the Evolution of Inclusion Body Myositis
|
N/A | |
| Completed |
NCT04421677 -
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
|
Phase 1 |